Dainippon Sumitomo Starts Joint Research With Osaka University
This article was originally published in PharmAsia News
Dainippon Sumitomo announced Oct. 23 that the company will collaborate with Osaka University on neuroscience research. The company will establish a neuropsychiatry drug discovery consortium with five divisions of the university's medical and pharmaceutical schools. The first research phase is planned for three years, from November 2008 to October 2011, and the company plans to invest ¥300 million in the project. Osaka University has conducted gene level research and aims to develop new drugs based on the research through forming alliances with pharmaceutical companies. (Click here for more - Japanese language)
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.